Skip to main content
SpringerLink
Log in

Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rats treated chronically with neuroleptics develop vacuous chewing movements (VCMs), similar in some respects to tardive dyskinesia (TD) in man. The VCM syndrome was used as a model of TD to examine the ability of increased neuroleptic doses to produce long-term suppression of dyskinetic movements. The incidence and persistence of the VCM syndrome in individual rats were also assessed to look for affected and unaffected subgroups. Rats were initially treated for 15 weeks with haloperidol decanoate. For the next 21 weeks, half the group received a 50–150% increase in dose while the other half continued to receive the same dose. Animals were also followed during a 28-week withdrawal period. Total VCM ratings showed a skewed distribution, with some rats exhibiting few movements while others developed marked and persistent movements. Increasing doses did not suppress VCMs, nor did they exacerbate movements during the withdrawal period. To the extent that the VCM syndrome models TD, the absence of long-term suppression of the VCM syndrome suggests that, at this dosage range, increasing depot neuroleptic doses may not be a useful long-term strategy for TD suppression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • APA Task Force on Tardive Dyskinesia, (1992) Tardive dyskinesia — a Task Force Report of the American Psychiatric Association, APA Press, Washington DC

    Google Scholar 

  • Barnes TR, Wiles DH (1983) Variation in oro-facial tardive dyskinesia during depot antipsychotic drug treatment. Psychopharmacology 81:359–362

    Article  PubMed  Google Scholar 

  • Bartko JJ, Carpenter WT (1976) On the methods and theory of reliability. J Nerv Ment Dis 163:307–317

    PubMed  Google Scholar 

  • Bergen JA, Eyland EA, Campbell JA, Jenkings P, Kellehear K, Richards A, Beumont PJV (1989) The course of tardive dyskinesia in patients on long-term neuroleptics. Br J Psychiatry 154:523–528

    PubMed  Google Scholar 

  • Curran JP (1973) Management of tardive dyskinesia with thiopropazate. Am J Psychiatry 130:925–927

    PubMed  Google Scholar 

  • Doongaji DR, Jeste DV, Jape NM, Sheth AS, Apte JS, Vahia VN, Desai AB, Parkih MD, Rathi LG, Ghandi MH, Parikh RM, Thatte S, Bharadwaj J (1982) Effects of intravenous metoclopramide in 81 patients with tardive dyskinesia. J Clin Psychopharmacol 2:376–379

    PubMed  Google Scholar 

  • Egan MF, Hyde TH, Albers GW, Elkashef A, Alexander RC, Reeve A, Blum A, Saenz RE, Wyatt RJ (1992) Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 149:773–777

    PubMed  Google Scholar 

  • Farde L, Nordstrom A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiat 49:538–544

    PubMed  Google Scholar 

  • Frangos E, Christodoulides H (1975) Clinical observations on the treatment of tardive dyskinesia with haloperidol. Acta Psychiatr Belg 75:19–32

    PubMed  Google Scholar 

  • Gale K (1980) Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in substantia nigra. Nature 283:569–570

    Article  PubMed  Google Scholar 

  • Gerlach J, Casey DE (1983) Sulpiride in tardive dyskinesia. Acta Psychiatr Scand (suppl) 311[69]:93–101

    Google Scholar 

  • Gibbons RD, Dorus E, Ostrow DG, Pandey GN, Davis J, Levy D (1984) Mixture distrubutions in psychiatric research. Biol Psychiatry 19:935–961

    PubMed  Google Scholar 

  • Glazer WM, Hafez H (1990) A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophr Res 3:315–320

    Article  PubMed  Google Scholar 

  • Gunne LM, Haggstrom J-E (1983) Reduction in nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia. Psychopharmacology 81:191–194

    Article  PubMed  Google Scholar 

  • Gunne, LM, Growden J, Glaeser B (1982) Oral dyskinesia in rats following brain lesions and neuroleptic drug administration. Psychopharmacology 77:134–139

    Google Scholar 

  • Gunne LM, Andersson U, Bondesson U, Johansson P (1986) Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol Biochem Behav 25:897–901

    Google Scholar 

  • Hess EJ, Norman AB, Creese I (1988) Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on Dland D2 dopamine receptors. J Neurosci 8[7]:2361–2370

    PubMed  Google Scholar 

  • Hyde TH, Egan MF, Wing L, Wyatt RJ, Weinberger DR, Kleinman J (1995) Persistent catalepsy is associated with persistent, severe vacuous chewing movements in rats treated with very long-term haloperidol decanoate. Psychopharmacology (in press)

  • Jann MW, Ereshefsky L, Saklad SR (1985) Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 10:315–333

    PubMed  Google Scholar 

  • Jellinek T, Gardos G, Cole J (1981) Adverse effects of antiparkinson drug withdrawal. Am J Psychiatry 138:1567–1571

    PubMed  Google Scholar 

  • Jeste DV, Wyatt RJ (1979) In search of treatment for tardive dyskinesia: review of the literature Schizophr Bull 5:251–293

    PubMed  Google Scholar 

  • Jeste DV, Wyatt RJ (1982) Therapeutic strategies against tardive dyskinesia: two decades of experience. Arch Gen Psychiatry 39:803–816

    PubMed  Google Scholar 

  • Jeste DV, Lohr JB, Clark, K, Wyatt RJ (1988) Pharmacological treatment of tardive dyskinesia in the 1980s. J Clin Psychopharmacol 8:38S-48S

    PubMed  Google Scholar 

  • Johansson P, Casey DE, Gunne LM (1986) Dose-dependent increases in rat spontaneous chewing rates during long-term administration of haloperidol but not clozapine. Psychopharmacol Bull 22:1017–1019

    Google Scholar 

  • Jus A, Jus K, Fontaine P (1979) Long term treatment of tardive dyskinesia. J Clin Psychiatry 40:72–77

    PubMed  Google Scholar 

  • Kazamatsuri H, Chien C-P, Cole JO (1972) Treatment of tardive dyskinesia II. short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Arch Gen Psychiatry 27:100–103

    PubMed  Google Scholar 

  • Kazamatsuri H, Chien C-P, Cole JO (1973) Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry 130:479–483

    PubMed  Google Scholar 

  • Klawans HL, Tanner CM, Barr A (1984) The reversibility of “permanent” tardive dyskinesia. Clin Neuropharmacol 7:153–159

    PubMed  Google Scholar 

  • Khot V, Egan MF, Hyde TM, Wyatt RJ (1992) Neuroleptics and classical tardive dyskinesia, In: Lang AE, Weiner WJ (eds) Drug-induced movement disorders. Futura, Mount Kisco, N.Y., pp 121–166

    Google Scholar 

  • Korsgaard S, Noring U, Gerlack J (1984) Fluperlapine in tardive dyskinesiaand parkinsonism. Psychopharmacology 39:803–816

    Google Scholar 

  • Leiberman J, Lesser M, Johns C, Pollack S, Saltz B, Kane J (1988a) Pharmacological studies of tardive dyskinesia. J Clin Psychopharmacol 8:57S-63S

    PubMed  Google Scholar 

  • Leiberman J, Pollack S, Lesser M, Kane J (1988b) Pharmacological characterization of tardive dyskinesia. J Clin Psychopharmacol 8:254–260

    PubMed  Google Scholar 

  • Levy AD, See RE, Levin ED, Ellison GD (1987) Neuroleptic-induced oral movements in rats: methodological issues. Life Sci 41:1499–1506

    Article  PubMed  Google Scholar 

  • Mithani S, Atmadja S, Baimbridge KG, Fibiger HC (1987) Neuroleptic-induced oral dyskinesias: effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyltransferase activities

  • Owens DG, Johnstone EC, Frith CD (1982) Spontaneous involuntary disorders of movement. Arch Gen Psychiatry 39:452–461

    PubMed  Google Scholar 

  • Piazza PV, Deminiere JM, Le Moal M, Simon H (1989) Factors that predict individual vulnerability to amphetamine self-administration. Science 246, 1511–1513

    Google Scholar 

  • Rifkin A, Quitikin F, Kane J, Struve F, Klein DF (1978) Are prophylactic antiparkinson drugs necessary? Arch Gen Psychiatry 35:483–489

    PubMed  Google Scholar 

  • Roxburgh PA (1970) Treatment of persistent phenothiazine-induced oral dyskinesia. Br J Psychiatry 116:277–280

    PubMed  Google Scholar 

  • Rupniak NMJ, Jenner P, Marsden CD (1985) Pharmacological characterization of spontaneous or drug-associated purposeless chewing movements in rats. Psychopharmacology 85:71–79

    Article  Google Scholar 

  • Rupniak NMJ, Prestwick SA, Horton RW, Jenner P, Marsden CD (1987) Alterations in cerebral glutamic acid decarboxylase and [3H]-flunitrazepam binding during continuous treatment of rats for one year with haloperidol, sulpiride, or clozapine. J Neurol Transm 68:113–125

    Article  Google Scholar 

  • See R, Ellison G (1990) Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia. Eur J Pharmacol 181:175–186

    Article  PubMed  Google Scholar 

  • See RE, Aravagiri M, Ellison GD (1989) Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2 but not dopamine D-1 receptors. Life Sci 44:229–236

    Article  PubMed  Google Scholar 

  • Singer K, Cheng MN (1971) Thiopropazate hydrochloride in persistent dyskinesia. Br Med J 4:22–25

    PubMed  Google Scholar 

  • Smith JS, Kiloh LG (1979) Six month evaluation of thiopropazate hydrochloride in tardive dyskinesia. J Neurol Neurosurg Psychiatry 42:576–579

    PubMed  Google Scholar 

  • Steinpreis RE, Baskin P, Salamone JD (1993) Vacuous jaw movements induced by sub-chronic administration of haloperidol: interactions with scopalamine. Psychopharmacology 111:99–105

    PubMed  Google Scholar 

  • Tamminga CA, Dale JM, Goodman L, Kaneda H, Kaneda N (1990) Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology 102:474–478

    Article  PubMed  Google Scholar 

  • Waddington JL (1990) Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology 101:431–447

    PubMed  Google Scholar 

  • Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1983) Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science 220:530–532

    PubMed  Google Scholar 

  • Waddington JL, Youssef HA, O'Boyle KM, Molloy AG (1986a) A reappraisal of abnormal involuntary movements (tardive dyskinesia) in schizophrenia and other disorders: animal models and alternative hypotheses. In: Winlow W, Markstein T (eds) The neurobiology of dopamine systems. Manchester University Press, Manchester, pp 266–286

    Google Scholar 

  • Waddington JL, Molloy AG, O'Boyle KM, Youssef HA (1986b) Spontaneous and drug-induced dyskinesias in rodents in relation to ageing and long-term neuroleptic treatment: relationship to tardive dyskinesia. In: Shagass C, Josiassen RC, Bridger W, Weiss K, Stoff D, Simpson G (eds) Biological psychiatry 1985. Elsevier, N.Y., pp 1151–1153

    Google Scholar 

  • Waddington JL, Molloy AG, O'Boyle KM (1988) Behavioral effects of long-term treatment with further typical neuroleptics and selective D-2 dopamine receptor antagonists in young vs aged animals. In: Sandler M, Dahlstrom A, Belmaker R (eds) Progress in catecholamine research. Part B: Central aspects. Liss, N.Y., pp 43–46

    Google Scholar 

  • Weiden PJ, Mann JJ, Haas G, Mattson M, Frances A (1987) Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 144: 1148–1153

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuropsychiatry Branch, National Institute of Mental Health, NIMH Neuroscience Research Center at St. Elizabeths, 2700 M.L. King Jr. Ave., S.E., 20032, Washington, DC, USA

    Michael F. Egan & Richard Jed Wyatt

  2. Clinical Brain Disorders Branch, National Institute of Mental Health, NIMH Neuroscience Research Center at St. Elizabeths, 2700 M.L. King Jr. Ave., S.E., 20032, Washington, DC, USA

    Thomas M. Hyde & Joel E. Kleinman

Authors
  1. Michael F. Egan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Jed Wyatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas M. Hyde
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joel E. Kleinman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Egan, M.F., Wyatt, R.J., Hyde, T.M. et al. Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose. Psychopharmacology 117, 74–81 (1995). https://doi.org/10.1007/BF02245101

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02245101

Key words

Search

Navigation